

CLINICAL INFORMATION

Gestational age: 11 + 2	Pregnancy type: Singleton	IVF pregnancy: No	Oocytes:
Clinical indication: Clinical history, Other(Other)			

myPrenatal		Fetal fraction: 9%
CHROMOSOMES TESTED	RESULTS CONSISTENT WITH	INTERPRETATION
Chromosomes 21, 18, 13	Absence of aneuploidy	Low risk of aneuploidy Regular pregnancy follow-up
Fetal sex	Absence of Y Chromosome	Female fetus
Sex chromosomes	Presence of monosomy X	High risk of aneuploidy Genetic counseling to evaluate confirmation of the result is recommended
Other chromosomes	Absence of aneuploidy	Low risk of aneuploidy Regular pregnancy follow-up
Deletions and duplications (CNVs) > 7Mb	Absence of deletions and duplications	Low risk of deletions and duplications Regular pregnancy follow-up

CLINICAL NOTE

Sequencing data analysis resulted in an increased risk for Monosomy X and result confirmation with diagnostic test (Amniocentesis or CVS) is recommended. In absence of concordant ultrasound markers, Amniocentesis would be preferable to avoid possible discrepancies due to confined placental mosaicism.

ANALYSIS METHOD

Cell-free DNA extraction from plasma, paired-end Next Generation Sequencing (NGS) and bioinformatic analysis to determine the risk of aneuploidy as requested (VeriSeq NIPT v2, Illumina Inc. CE-IVD).

LIMITATIONS AND PERFORMANCE

myPrenatal is a test designed to screen for common fetal trisomies (chromosomes 21, 18 and 13), as also for rare aneuploidies and partial imbalances (CNVs) of at least 7 megabases (Mb) in all the autosomes. In singleton pregnancies it is possible to extend the analysis to sex chromosomes aneuploidies and fetal sex determination; in twin pregnancies only the presence or absence of the Y chromosome can be evaluated. The test is validated for singleton or twin pregnancies of at least 10 weeks of gestation.

Test results might not reflect the true fetal chromosome constitution as false positives or false negatives could occur. Among the main known causes of discrepancies, the most frequent are due to biological factors included but not limited to the presence of a vanishing twin, fetal mosaicism of low proportion, confined placental mosaicism or unrecognized maternal chromosomal abnormalities. In pregnancies with a non-evolving co twin (or vanishing twin), the result could reflect its chromosome constitution.

myPrenatal has not been designed to determine the risk of other genetic disorders such as chromosomal mosaicisms, triploidy, partial aneuploidies of less than 7Mb and single gene defects so that a low risk result does not guarantee a healthy pregnancy or fetus and does not eliminate the presence of other genetic or structural alterations such as neural tube defects.

Some rare chromosomal aneuploidies can only occur in mosaic form. The clinical consequences depend on the chromosome involved and may not be elucidated prenatally.

Performance data:

	Trisomy 21	Trisomy 18	Trisomy 13	Other aneuploidies	CNVs (>7Mb)	Fetal sex results concordance		
Sensitivity	>99%	>99%	>99%	96.40%	74.10%	100%	90.5%	91.7%
Specificity	99,90%	99,90%	99,90%	99.80%	99.80%	XX, XY, XXX, XXY	XO	XXY

VeriSeq NIPT v2 CE-IVD Product insert (Singleton gestations excluding mosaics)

DISCLAIMER

Non-invasive prenatal screening based on the analysis of the cell-free DNA cannot be considered diagnostic tests. The results should be interpreted with all the clinical information available by the prescribing physician to provide appropriate advice on pregnancy management. No irreversible clinical decisions should be made based solely on these results. A result consistent with the presence of a chromosomal abnormality should always be confirmed by a prenatal diagnostic test performed on fetal samples obtained by an invasive procedure (i.e. amniocentesis or chorionic villus sampling).

VALIDATION

Technical director: Dr. Vincenzo Cirigliano

Medical director: Dr. Luis Izquierdo

Report validated by: Dr. Elena Ordoñez